Avery Dennison has announced the final results of its cash tender offers for two series of senior notes, which expired on November 12, 2026. The company accepted $233 million of its 5.750% notes due 2033 on a prorated basis, upsizing the accepted amount by $8 million, while no 6.000% notes due 2033 were accepted due to their lower acceptance priority. This move is intended as a debt reduction step, offering cash to tendering holders of the accepted notes.

Investing.com reports on Mink Therapeutics Inc.'s Form 8K filing for November 12. The article provides the title of the SEC filing and notes the stock symbol INKT, which was down 6.79%. It's primarily a brief notification of the regulatory filing.

This article announces that FIRST INTERNET BANCORP 6.0% SUB NT FXD FLTG DUE 30/06/2029 will go ex-dividend on November 13th, 2026. Shareholders can expect a dividend payment of 0.52816 USD per share. This information is crucial for investors tracking dividend distributions.

Jade Biosciences announced its Q3 2026 financial results, reporting $475.7 million in cash and investments, expected to fund operations into Q4 2028. The company is advancing its clinical pipeline, with the JADE101 Phase 3 trial in IgA nephropathy expected to start in Q4 2026 and interim data from other trials anticipated in 2027. Brad Dahms' role was expanded to Chief Financial Officer and Chief Business Officer to lead business development and corporate strategy.

Innventure Inc. (INV) is prioritizing liquidity defense through strategic reviews and cost reductions, while its Accelsius initiative progresses with hyperscaler and OEM validation. The company reported a Q3 2026 net loss of $323.46M, largely due to a non-cash goodwill impairment; excluding this, the net loss was $10.38M. This information is based on an AI-generated summary of Innventure's Q3 2026 Audio Transcript from November 12, 2026.

Robert W. Baird has upgraded Domino's Pizza (NASDAQ:DPZ) stock rating from "neutral" to "outperform" and increased its price target to $400, suggesting a potential 20% upside. This upgrade comes after Domino's Pizza reported quarterly earnings that surpassed analyst expectations, with EPS of $4.60 against an expected $4.33, and a 3.4% year-over-year revenue increase to $1.19 billion. Analyst sentiment remains generally positive, with a consensus "Moderate Buy" rating and an average price target of $383.45.

Hilton Worldwide Holdings has been named No. 1 on Fortune and Great Place To Work’s World’s Best Workplaces list for the second consecutive year, marking its third top finish in four years. The company was recognized in 73 countries and ranked first in 21, including Europe, Asia, and Latin America. Hilton emphasizes promoting leaders from frontline positions, with 93% of its hotel leaders starting in such roles and a significant portion reaching management within three years.

Zacks Research has upgraded Lakeland Industries (NASDAQ:LAKE) from a "strong sell" to a "hold" rating, though other analysts remain mixed. The company's stock opened at $9.29, down 1.3%, and its share price is below its 50-day and 200-day moving averages. Lakeland Industries reported a quarterly loss of $0.50 per share, missing analyst expectations, and revenue of $50.14 million, also below consensus.

Zacks Research has downgraded Monro Muffler Brake (NASDAQ:MNRO) from a "hold" to a "strong sell" rating. This follows other analyst price target cuts, though the consensus remains "Hold" with an average target of $23. The company recently reported a quarterly loss of $0.01 per share, missing estimates, and its revenue decreased by 1.8% year over year.

World Child Cancer and Amgen have forged a strategic partnership since 2023, focusing on improving care for children with cancer through shared expertise and trust. This collaboration has strengthened healthcare teams, enhanced access to treatment, and supported affected children and families. Key individuals like Sean Lybrand, Philip Anderson, Jon Hicks, Ponda Motsepe-Ditshego, and Paul Burton from Amgen have been instrumental in this progress, providing advocacy, clinical expertise, program management, and leadership to champion equitable access to healthcare.